Merieux Equity Partners

About Merieux Equity Partners

Mérieux Equity Partners is a leading European healthcare-specialised investment firm with €1.6 billion of assets under management as of December 2024, founded in 2009 and headquartered in Lyon. The firm operates through two dedicated platforms: Innovation (venture capital) and Buyout (growth and buyout), supporting the healthcare ecosystem across early-stage biotech innovation through to mid-cap healthcare buyout transactions, with the platform aligned with the broader Institut Mérieux life sciences industrial heritage.

Investment thesis

Mérieux Equity targets European and selectively North American healthcare companies across the development lifecycle, deploying dedicated venture commitments through the Innovation platform (early-stage biotech and HealthTech) plus growth and buyout equity through the Buyout platform (mid-cap healthcare services and products). Equity ticket sizes vary by strategy from venture-stage early commitments through to mid-cap healthcare growth equity positions. The exclusive healthcare sector focus enables deep clinical and regulatory expertise across portfolio companies.

Recent activity

Recent realised exits include Mabtech (healthcare, 2024), Mablink Bioscience (healthcare, 2023), Physioassist (healthcare, 2023), DOC Generici (healthcare, 2022) and Ivantis (healthcare, 2022), reflecting active distribution across the healthcare franchise. The platform tracks 6 funds, 34 active portfolio companies and 17 realised exits across the dual Innovation and Buyout programmes.

Frequently asked questions

What investment strategy does Merieux Equity Partners focus on?

Merieux Equity Partners focuses on VC, Growth, Buyout strategies in the private equity space.

How many portfolio companies does Merieux Equity Partners have?

Merieux Equity Partners has 33 active portfolio companies and 24 completed exits and 7 funds tracked on GP Intel.

Where is Merieux Equity Partners headquartered?

Merieux Equity Partners is headquartered in LYON, France.

What is Merieux Equity Partners's assets under management?

Merieux Equity Partners manages approximately €1.6B in assets under management.

When was Merieux Equity Partners founded?

Merieux Equity Partners was founded in 2018.

What sectors does Merieux Equity Partners invest in?

Merieux Equity Partners invests across Healthcare, Consumer.

What are Merieux Equity Partners's recent exits?

Recent realized exits by Merieux Equity Partners include: SWIXX BioPharma (2026) to SK Capital / Bain Capital Life Sciences; Ceva Sante Animale (2025) to ARCHIMED; Plantex (2025) to Nactarome; LabQuality (2025) to Aurevia; Theravia (2025) to Norgine; GTP Bioways (2024) to Olon Group; Mabtech (2024) to EQT; Mablink Bioscience (2023) to Eli Lilly and Company.